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Treatment of organophosphate poisoning with pralidoxime needs to be improved.
Here we have studied the pharmacokinetics of pralidoxime after its intramuscular
injection alone or in combination with avizafone and atropine using an auto-
injector device.
EXPERIMENTAL APPROACH
The study was conducted in an open, randomized, single-dose, two-way, cross-over
design. At each period, each subject received either intramuscular injections of
pralidoxime (700 mg), or two injections of the combination: pralidoxime (350 mg),
atropine (2 mg), avizafone (20 mg). Pralidoxime concentrations were quantified
using a validated LC/MS-MS method. Two approaches were used to analyse these
data: (i) a non-compartmental approach; and (ii) a compartmental modelling
approach.
KEY RESULTS
The injection of pralidoxime combination with atropine and avizafone provided a
higher pralidoxime maximal concentration than that obtained after the injection of
pralidoxime alone (out of bioequivalence range), while pralidoxime AUC values
were equivalent. Pralidoxime concentrations reached their maximal value earlier
after the injection of the combination. According to Akaike and to goodness of fit
criteria, the best model describing the pharmacokinetics of pralidoxime was a two-
compartment with a zero-order absorption model. When avizafone and atropine
were injected with pralidoxime, the best model describing pralidoxime
pharmacokinetics becomes a two-compartment with a first-order absorption model.
CONCLUSIONS AND IMPLICATIONS
The two approaches, non-compartmental and compartmental, showed that the
administration of avizafone and atropine with pralidoxime results in a faster
absorption into the general circulation and higher maximal concentrations,






















Publié sur Okina (http://okina.univ-angers.fr)
